|Bid||12.00 x 1400|
|Ask||12.25 x 1000|
|Day's Range||11.85 - 12.09|
|52 Week Range||11.57 - 20.71|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||5.32|
|Earnings Date||Oct 25, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Sep 08, 2015|
|1y Target Est||18.67|
Subscribe to Yahoo Finance Plus to view Fair Value for INVA
Theravance Biopharma Inc (NASDAQ: TBPH) is buying back over 9.6 million shares from GSK plc (NYSE: GSK) for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back $95 million from its existing investors "in the near term" and another $60 million in its shares on the open market. In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023. Related content: Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patien
BURLINGAME, Calif., September 08, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.
It hasn't been the best quarter for Innoviva, Inc. ( NASDAQ:INVA ) shareholders, since the share price has fallen 12...